XNAS · Healthcare · Biotechnology
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | Q1 2026 | 8.38 | 9.47 | +13.01% | $3.60B | ✅ Beat | +0.00% | +5.05% | -10.43% |
| 2026-01-30 | Q4 2025 | 9.69 | 11.44 | +18.06% | $3.88B | ✅ Beat | +2.08% | +5.94% | +6.66% |
| 2025-10-28 |
| Q3 2025 |
| 8.84 |
| 11.83 |
| +33.82% |
| $3.75B |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-01 | Q2 2025 | 7.55 | 12.89 | +70.73% | $3.68B | ✅ Beat | — | — | — |
| 2025-04-29 | Q1 2025 | 8.82 | 8.22 | -6.80% | $3.03B | ❌ Miss | — | — | — |
| 2025-02-04 | Q4 2024 | 11.19 | 12.07 | +7.86% | $3.79B | ✅ Beat | — | — | — |
| 2024-10-31 | Q3 2024 | 11.69 | 12.46 | +6.59% | $3.72B | ✅ Beat | — | — | — |
| 2024-08-01 | Q2 2024 | 10.53 | 11.56 | +9.78% | $3.55B | ✅ Beat | — | — | — |
Showing last 8 quarters.